ACTRN12606000257561.

Study name	Safety and efficacy of pentoxifylline as a treatment for preventing the progression of NEC in preterm neonates
Methods	Randomised, placebo‐controlled trial
Participants	Premature neonates < 32 weeks' gestation with stage 2 or 3 NEC
Interventions	Pentoxifylline at 5 mg/kg/h for 12 hours for 2 days followed by infusion for 6 hours a day for the next 4 days OR equal volume of placebo in controls
Outcomes	Primary: efficacy and safety of pentoxifylline in preventing the progression of NEC or death, or both Secondary: reduction in plasma tumour necrosis factor alpha levels, extent of bowel resection at surgery, duration of hospital stay and total parenteral nutrition support, and duration to full enteral feeds
Starting date	Late 2014
Contact information	Sanjay Patole, email: Sanjay.Patole@health.wa.gov.au
Notes	This trial has not recruited any patients till data (as of March 2023).